November 20, 2024

CPPD Disease: More Common Than Previously Thought

In a paradigm shift for treating acute CPPD crystal arthritis, the 2023 COLCHICORT trial showed prednisone matched colchicine's efficacy with better tolerability in older patients, challenging long-held treatment assumptions.

Conexiant

November 20, 2024

CPPD Disease: More Common Than Previously Thought

In a paradigm shift for treating acute CPPD crystal arthritis, the 2023 COLCHICORT trial showed prednisone matched colchicine's efficacy with better tolerability in older patients, challenging long-held treatment assumptions.

Conexiant

November 19, 2024

Gantenerumab Linked to ARIA Risk in Early Alzheimer's Disease

86% of ARIA-E cases occurred within the first 64 weeks of gantenerumab treatment, with APOE ε4 homozygotes showing nearly 5-fold increased risk.

Conexiant

November 19, 2024

Novel Stroke Drug Shows 12-Hour Window

Despite a median treatment time of 9.5 hours after stroke onset - more than twice the current therapeutic window - JX10 showed significantly better functional outcomes than placebo with no symptomatic intracranial hemorrhage events.

Conexiant

November 19, 2024

Can Fluid Restriction Stop MDMA Hyponatremia?

A 433% oxytocin increase—not vasopressin—correlated with MDMA-induced hyponatremia, with fluid restriction preventing all cases in a controlled setting.

Conexiant

November 14, 2024

FDA Approves Gene Therapy for Rare Disorder

Reuters

November 12, 2024

Eight Off-Label Treatments Show Promise for ALS

While individual treatments targeting neuroinflammation, oxidative stress, or mitochondrial dysfunction have historically disappointed in ALS trials, eight alternative treatments showing multi-mechanism effects warrant further investigation, according to a comprehensive review of 15 years of clinical data.

Conexiant

November 12, 2024

How Immune Cells Sabotage the Heart in Duchenne Muscular Dystrophy

New research highlights macrophages’ role in disrupting the heart's nerve communication, offering potential targets for therapy.

Conexiant

November 11, 2024

Child Neurodevelopment After SARS-CoV-2 Exposure

New research shows that prenatal SARS-CoV-2 exposure was linked to a slight increase in self-regulatory behavior at six months, with no significant neurodevelopmental differences by age two.

Conexiant